Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension | Zendy

David A. Calhoun | Zendy; William B. White | Zendy; Henry Krum | Zendy; Weig Guo | Zendy; Georgina Bermann | Zendy; Angelo J. Trapani | Zendy; Martin Lefkowitz | Zendy; Joël Ménard | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension

Author(s) -

David A. Calhoun,

William B. White,

Henry Krum,

Weig Guo,

Georgina Bermann,

Angelo J. Trapani,

Martin Lefkowitz,

Joël Ménard

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.029892

Subject(s) - aldosterone , eplerenone , medicine , aldosterone synthase , tolerability , placebo , blood pressure , ambulatory blood pressure , endocrinology , ambulatory , essential hypertension , adrenocorticotropic hormone , spironolactone , hormone , adverse effect , renin–angiotensin system , alternative medicine , pathology

LCI699, a novel inhibitor of aldosterone synthase, reduces serum aldosterone, and may have benefit in the treatment of hypertension.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research